SCHEMBL503308

SCHEMBL503308

CCOc1ccc(CC(=O)O)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4B P0C869 1/20 0.58
SMN1; SMN2 Q16637 3/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
HPGD P15428 2/20 0.57
RXRA P19793 1/20 0.56
RXRB P28702 1/20 0.56
RXRG P48443 1/20 0.56
NQO1 P15559 1/20 0.56
ALDH1A1 P00352 3/20 0.55
MAPT P10636 1/20 0.55
LTB4R Q15722 4/20 0.55
LTB4R2 Q9NPC1 4/20 0.55
POLB P06746 2/20 0.54
MAPK1 P28482 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
CNR2 P34972 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2528810 0.98 PLA2G4B (0.56) PLA2G4BSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL469914 0.94 RXRA (0.63) PLA2G4BSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL11969487 0.91 FFAR1 (0.64)
3-Methylbutanoic Acid SCHEMBL6891960 0.88 SMN1; SMN2 (0.56) PLA2G4BSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL1285778 0.85 PLA2G4B (0.77) PLA2G4BSMN1; SMN2HPGDALDH1A1L3MBTL1
SCHEMBL8735351 0.85 ERCC5 (0.55) PLA2G4BSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL1443020 0.85 LMNA (0.70) PLA2G4BSMN1; SMN2HPGDALDH1A1LTB4R
(2E)-Hexenoic Acid SCHEMBL8131000 0.84 ALDH1A1 (0.56) PLA2G4BSMN1; SMN2NPC1RAB9AHPGD
(2E)-Hexenoic Acid SCHEMBL8131008 0.84 ALDH1A1 (0.56) PLA2G4BSMN1; SMN2NPC1RAB9AHPGD
SCHEMBL2628188 0.84 POLB (0.59) SMN1; SMN2NPC1RAB9AHPGDNQO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
CN-118771963-A Method for realizing double-carbon functional conversion of olefin through carboxylic acid decarboxylation by using sulfur hexafluoride as oxidizing agent 国网安徽省电力有限公司电力科学研究院 2024-10-15 CN claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
CN-116987216-A Supercritical carbon dioxide thickener containing siloxane branched chains and preparation method thereof 西南石油大学 2023-11-03 CN claimed
CN-114317068-B Lubricating oil for automobile engine and preparation method and application thereof 济南赛邦石油化学有限公司 2022-08-26 CN claimed
CN-113200934-B Compound containing benzomorpholone-biphenyl skeleton and preparation method and application thereof 郑州大学 2022-05-31 CN claimed
CN-114317068-A Lubricating oil for automobile engine and preparation method and application thereof 济南赛邦石油化学有限公司 2022-04-12 CN claimed
CN-113200934-A Compound containing benzomorpholone-biphenyl skeleton and preparation method and application thereof 郑州大学 2021-08-03 CN claimed
WO-2021018699-A1 CANNABINOID RECEPTOR SUBTYPE 2 STIMULATOR INHIBITING ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) 2021-02-04 WO claimed
EP-3771713-A1 CANNABINOID RECEPTOR SUBTYPE 2 STIMULATOR INHIBITING ACETYLCHOLINESTERASE AND BUTYRYLCHOLINESTERASE Julius-Maximilians-Universität Würzburg (DE) 2021-02-03 EP claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
CN-1521164-A Pyran isoflavone molluscacide synthesizing method and formulation 中国人民解放军南京军区联勤部军事医 2004-08-18 CN claimed
US-5663029-A DEVELOPMENT OF LATENT IMAGE, TRANSFERRING TO FORM RECORDING SHEETS, COATING A SUBSTRATE USING POLYMERS XEROX CORPORATION (US) 1997-09-02 US claimed
WO-1991018523-A1 INGESTIBLES CONTAINING SUBSTANTIALLY TASTELESS SWEETNESS INHIBITORS AS BITTER TASTE REDUCERS OR SUBSTANTIALLY TASTELESS BITTER INHIBITORS AS SWEET TASTE REDUCERS BIORESEARCH, INC. (US) 1991-12-12 WO claimed
EP-0125049-B1 METHOD OF INHIBITING SWEETNESS TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1986-07-30 EP claimed
EP-0125049-A1 Method of inhibiting sweetness TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1984-11-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 PLA2G4B 3566/4885SMN1; SMN2 4149/4885NPC1 3732/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 PLA2G4B 3544/4885SMN1; SMN2 3422/4885NPC1 3601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.